Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POETYK SjS-1
2023-503327-26-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing deucravacitinib with placebo (2 arms). Primary endpoint: Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index. Planned start Jan 2024; status: authorised.
02
Drugs
deucravacitinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2023-503327-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503327-26-00.